Compare Cigna Corp (CI) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs 22nd Century Group Inc — how do they compare? Cigna Corp trades at $272.76 (market cap $73.56B), while 22nd Century Group Inc trades at $4.46 (market cap $1.52M). The key difference: Cigna Corp is far larger — about 48394.7× 22nd Century Group Inc's market cap, and Cigna Corp pays a 2.24% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| CI | XXII | |
|---|---|---|
Market Cap | $73.56B | $1.52M |
Sector | Health | Technology |
52-Week High | $311.00 | $801.00 |
52-Week Low | $244.41 | $3.72 |
Enterprise Value | $98.27B | -$6.71M |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $278.40, down 1.45% on the day, with a bearish technical signal but strong fundamentals including a P/E of 11.51 and ROE of 15.49%. Recent Q2 2026 earnings beat expectations at $7.78 per share, and the company raised its full-year EPS guidance. The stock is supported by consistent dividend payments and robust cash flow from operations of $9.60 billion in 2025.
The outlook is positive with a consensus price target of $338.90, implying 22% upside. Key opportunities include steady earnings growth and capital returns, while risks involve healthcare cost pressures and competitive dynamics. Analyst sentiment is strongly bullish with 73.68% buy ratings, though technical indicators suggest near-term caution.
XXII trades at $4.46, up 2.53% today, with a neutral technical signal and bearish moving averages. The company shows deep losses with a net income margin of -65.76% and negative ROE of -130.19%, though it beat earnings in Q3 2025. Recent news highlights VLN® retail expansion in California and New York, and a reverse stock split on June 12, 2026. Cash flow remains dependent on financing, with operating cash flow negative at -$7.72 million in 2025.
Outlook is speculative; analyst consensus is 75% buy with growth potential from VLN® market expansion, but high execution and regulatory risks persist. Investment hinges on revenue scaling to offset persistent losses, with stock volatility expected near key resistance at $5.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
